Site Specific Antileishmanial Drug Delivery
Over the past decade progress has been made towards the rational development of drug delivery vesicles for the treatment of visceral leishmaniasis. After intravenous (IV) administration, foreign colloidal particles, such as phospholipid vesicles (liposomes) and nanoparticles, are rapidly cleared by the macrophages of the reticuloendothelial system (RES) — particularly those residing in the liver and spleen. While this natural distribution may cause serious limitations for the use of colloidal carriers in the treatment of a number of diseases, including solid tumours or metastases and cutaneous leishmaniasis, it offers considerable advantages in the treatment of visceral leishmaniasis.
KeywordsVisceral Leishmaniasis Cutaneous Leishmaniasis Antileishmanial Activity Leishmania Donovani Sodium Stibogluconate
Unable to display preview. Download preview PDF.
- Dutz, W., Agarval, N., Bashardost, M.Z., Bently, G. & Kindmark, C.O., (1987) Topical Therapy of Cutaneous Leishmaniasis with 2% Ketokonazole Oitment and DMSO Int. J. Dermatology 26, 199Google Scholar
- Hart, D.T. (1987) Leishmania host-parasite interactions: The development of chemotherapeutic targets and specific drug delivery systems. I. Lipoprotein-mediated antileishmanial chemotherapy. In: Host-Parasite Cellular and Molecular Interactions in Protozoal Infections, eds K-P. Chang & D. Snary, Springer-Verlag, Berlin.Google Scholar
- New, R.R.C., Chance, M.L. and Heath, S. (1983) Liposome Therapy For Experimental Cutaneous and Visceral Leishmaniasis. Biol. Cell 47, 59–64Google Scholar
- Van Berkel T.J.C., Kruijt J.K., Harkes L., Nagelkerke J.F., Spanjer H. & Kempen H-J. (1986) In: Site-specific Drug Delivery. Eds Tomlinson and Davis. John Wiley & Sons Ltd. London.Google Scholar